Zacks Research Upgrades Medline (NASDAQ:MDLN) to Hold

Medline (NASDAQ:MDLN – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday, Zacks reports.

Other equities analysts have also recently issued reports about the company. Mizuho decreased their price objective on Medline from $48.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, October 22nd. Wall Street Zen raised Medline from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Royal Bank Of Canada reduced their price target on shares of Medline from $53.00 to $46.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Robert W. Baird set a $42.00 price target on shares of Medline in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, November 9th. Twenty-three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.08.

Get Our Latest Analysis on MDLN

Medline Trading Down 3.4%

NASDAQ MDLN opened at $37.84 on Wednesday. The company has a quick ratio of 2.51, a current ratio of 4.04 and a debt-to-equity ratio of 0.65. The stock’s 50-day simple moving average is $35.60 and its two-hundred day simple moving average is $39.25. Medline has a twelve month low of $31.37 and a twelve month high of $50.88. The company has a market capitalization of $49.77 billion and a price-to-earnings ratio of 86.00.

Medline (NASDAQ:MDLN – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.21% and a net margin of 1.84%. Research analysts forecast that Medline will post 1.58 EPS for the current fiscal year.

Insider Buying and Selling at Medline

In other news, major shareholder Private Ltd Gic sold 2,088,987 shares of the business’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the sale, the insider owned 16,453,806 shares of the company’s stock, valued at approximately $576,705,900.30. The trade was a 11.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 6,348,676 shares of company stock valued at $224,525,137. Insiders own 0.81% of the company’s stock.

Hedge Funds Weigh In On Medline

A number of large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock valued at $506,546,000 after purchasing an additional 887,240 shares during the last quarter. Banque Pictet & Cie SA boosted its stake in shares of Medline by 2.0% during the third quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock valued at $258,692,000 after purchasing an additional 142,939 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Medline by 233.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock worth $222,500,000 after purchasing an additional 3,500,000 shares during the last quarter. Durable Capital Partners LP grew its holdings in shares of Medline by 80.2% in the third quarter. Durable Capital Partners LP now owns 4,734,627 shares of the company’s stock worth $164,292,000 after purchasing an additional 2,107,306 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Medline by 30,255.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after purchasing an additional 2,691,529 shares during the last quarter.

Latest Medline News

Here’s some of the latest news about MDLN:

  • Positive Sentiment: Several recent valuation articles argue Medline may be undervalued, estimating upside of about 19% to 33%; a separate report says analysts raised fair-value estimates. These are valuation opinions, not guarantees of future performance. Article Article Article
  • Negative Sentiment: Existing investors are selling 60 million Class A shares at $35.50 each, with an option for another 9 million. Medline will receive no proceeds; the offering price may weigh on the stock and the sale adds near-term supply, even though it is not a new issuance by the company. Article
  • Negative Sentiment: Medline has reported additional deaths in connection with its electric-bed recall, raising potential product-liability and reputational concerns. Separately, a law firm announced a securities-fraud investigation; this is an investigation announcement, not a finding of wrongdoing. Article Investigation announcement

About Medline

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Further Reading

Analyst Recommendations for Medline (NASDAQ:MDLN)

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.